Shop Now Contact

Anti-Human HER2 (Trastuzumab Biosimilar)

Cat # Size Price Quantity
5062011 mg$650

  Bulk/Custom

Product Details

CloneTrastuzumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionTrastuzumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
IsotypeHuman IgG1, L234A L235A P329G (LALAPG)
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenA431 cells overexpressing human EGFR
Clone Number4D5-8
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsCD340, HER2
RRIDAB_3739337
Target NameHER2, HER-2, ERBB2, CD340, MLN19, NEU, NGL, TKR1
Antibody TypeRecombinant
Research AreasMesenchymal Stem Cells, Embryogenesis, Cancer Marker, Cancer Immunology
See All FormatsClone Trastuzumab

Background Information

Trastuzumab is a recombinant humanized monoclonal antibody belonging to the immunoglobulin G1 (IgG1) subclass, engineered to specifically recognize the human epidermal growth factor receptor 2 (HER2, also known as ErbB2). Structurally, the molecule has a molecular weight of approximately 148 kilodaltons (kDa) and retains the typical Y-shaped configuration of IgG antibodies, consisting of two identical heavy chains and two identical light chains connected by disulfide bonds. Each heavy chain contains one variable (VH) domain and three constant (CH1-CH3) domains, while each light chain comprises one variable (VL) and one constant (CL) domain. Trastuzumab is produced in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, ensuring proper glycosylation and structural fidelity.

The antigen-binding sites of Trastuzumab, located within the complementarity-determining regions (CDRs) of its VH and VL domains, exhibit high specificity for an extracellular epitope on subdomain IV of the HER2 receptor. The binding interaction is stabilized by a network of hydrogen bonds and hydrophobic contacts, characterized by sub-nanomolar affinity. This precise molecular recognition prevents receptor interactions that influence downstream signaling, thus modulating various intracellular signaling cascades involved in cell proliferation and survival within experimental systems that model receptor-mediated signaling pathways.

This Fc-silent antibody mutant is genetically engineered with mutations in its tail (Fc region) that prevent it from activating the immune system's effector functions (like cell killing), allowing it to act purely as a blocker or binder without triggering unwanted inflammation.

Data Sheets

Anti-Human HER2 (Trastuzumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Human HER2 (CD340) Protein (C-His-Avi)

Biotin Human HER2 (CD340) Protein (C-His-Avi)

Human HER2 (CD340) Protein (C-His)

Anti-Human HER2 (Pertuzumab Biosimilar), Clone Pertuzumab

PE Human HER2 (CD340) Protein (C-His)

APC Human HER2 (CD340) Protein (C-His)

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.